Health Care Technology
Company Overview of Proteus Digital Health, Inc.
Proteus Digital Health, Inc. operates as a digital medicines company. The company focuses on developing products, services, and data systems based on integrating medicines with ingestible, wearable, mobile, and cloud computing. Its digital health feedback technology provides a view into an individual’s personal health choices and physiologic response, allowing patients to manage their health, and collaborate with caregivers and clinicians. Proteus Digital Health, Inc. was formerly known as Proteus Biomedical, Inc. and changed its name to Proteus Digital Health, Inc. in July 2012. Proteus Digital Health, Inc. was founded in 2001 and is headquartered in Redwood City, California.
2600 Bridge Parkway
Redwood City, CA 94065
Founded in 2001
Key Executives for Proteus Digital Health, Inc.
Co-Founder, Chief Executive Officer and President
Co-Founder and Chief Technology Officer
Co-Founder and Chief Medical Officer
Compensation as of Fiscal Year 2015.
Proteus Digital Health, Inc. Key Developments
FDA Expands the Indications for Use Statement for the Latest Generation of Proteus Digital Health, Inc.'s Ingestible Sensor Technology
Jul 2 15
Proteus Digital Health, Inc. announced that the FDA has expanded the Indications for Use statement for the latest generation of its Ingestible Sensor technology, enabling the device to be used as an aid in the measurement of medication adherence. To the company’s knowledge, this is the only device with an FDA-sanctioned claim for measuring medication adherence. An estimated 50% of do not take medicines as prescribed, potentially limiting the therapeutic effectiveness of medicine and resulting in $100-300 billion in avoidable healthcare costs in the US alone due to unnecessary escalation of treatment. There have been many efforts to address this challenge but no products have previously been cleared by the FDA for aiding in the measurement of adherence until now. When used with a medication, the Proteus Ingestible Sensor marks actual intake time, a quantifiable event that has allowed regulators to grant the expanded indication to the company. The Ingestible Sensor was approved by the FDA in 2012 and communicates with an adhesive patch, worn on the torso. The Proteus Patch records time of ingestion along with steps, rest and heart rate, and communicates to a mobile app via Bluetooth.
Proteus Digital Health Announces Key Executive Appointments
Jun 2 14
Proteus Digital Health(TM) raised $120 million from new investors through the company's most recent round of funding. Steve Fieler joins the executive team as Chief Financial Officer, leveraging ten years of senior leadership experience at Hewlett-Packard, most recently as CFO of HP's $4 billion in revenue software division. Jonathan Symonds CBE, Chairman of HSBC Bank Plc and former CFO of Novartis AG, has been appointed to the company's Board of Directors.
Proteus Digital Health Announces Executive Appointments
Apr 16 14
Proteus Digital Health(TM) announced expansion of the company's executive team and board of directors with the addition of three industry leaders across consumer technology and global pharmaceuticals. Charles Songhurst has been appointed to the Proteus Digital Health Board of Directors, bringing significant investment and technology expertise to the company. Songhurst is Founding Partner at Katana Capital. Dr. Markus Christen joins Proteus as Senior Vice President and Head of Global Development, driving creation of the company's digital medicines portfolio. Dr. Christen served as the Global Head of Strategy, Business Development and M&A for Molecular Diagnostics and eHealth at Novartis Pharma AG. Tony Levitan joins as Senior Vice President of People, and is focused on ensuring that the human aspects of the company continue to be as impressive as the intellectual property and new products.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|